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ABSTRACT 
A controlled blind study was carried out to establish the efficacy of Sodium Valproate as the 
first line of treatment in Acute Mania. Patients were studied over a period of 4 weeks. Using 
randomised table patients were assigned to either lithium or valproate. Decrease in the 
psychopathology was evident within 2-3 weeks. Valproate was found to be as effective as Lithium 
in controlling the manic episode. 
Key Words : Acute mania, sodium valproate, drug treatment 
Acute mania is associated with substantial 
negative personal, interpersonal and social 
consequences. Effective and rapid 
pharmacological control of the condition is a 
necessity and towards this a variety of agents 
are available currently. They are lithium, 
antipsychotics, benzodiazepines, anticonvulsants 
like carbamazepine, valproate etc. Review of 
literature by Licht (1998) recently reveals that 
there is diversity in the preference of agents as 
the first line of treatment in acute mania across 
countries Lithium continues to be used 
extensively both in USA and Europe. Valproate 
is the recommended agent in the North American 
continent in the recent times (Joffe,1993; 
APA.1994, Bowden.1996) Antipsychotics as the 
first line of treatment are losing ground in the West 
although it is still used as an adjunct especially in 
cases with psychotic symptoms (Soares et 
al ,1997) In India, in clinical practice 
antipsychotics and lithium continue to be the 
preferred drugs in acute mania. Published data 
from India on the efficacy of anticonvulsant like 
valproate in acute mania is not available Hence 
the present study was undertaken to validate the 
effectiveness of sodium valproate in comparison 
to lithium in the treatment of acute mania in the 
Indian population. 
MATERIAL AND METHOD 
The study was conducted at the 
Department of Psychiatry, National Institute of 
Mental Health & Neurosciences (NIMHANS), 
Bangalore. Consenting patients with an ICD-10 
diagnosis of mania or bipolar affective disorder 
(BPAD) currently mania were taken for the study. 
Written informed consent was obtained from the 
patients and a near relative. Due to practical 
reasons the study sample consisted of only male 
patients. The diagnosis was confirmed by two 
clinicians independently after a detailed 
psychiatric evaluation. All the patients in the study 
were admitted during the period of the trial - 4 
weeks Patients were in the age group of 16-45 
years Patients were eithor drug naive or had 
stopped medication one month before the current 
consutation. Patients with comorbid illness like 
epilepsy, substance abuse, personality disorders 
etc. were excluded from the study. Detailed 
physical examination was done Laboratory test 
(complete haemogram, liver function tests, renal 
function tests & thyroid function tests) were done. 
Patients were randomly assingned to two 
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groups - first group received lithium carbonate 
and second group received sodium valproate. 
Each patient had an equal chance of being 
included in either group I or II. The first author 
(HMP) who was blind to the medication received 
by the patients serially rated patients. Beigel's 
Mania Rating Scale (BMRS) - a scale with proven 
reliability and validity was used for rating the 
severity of the psychopathology (Beigel,1971). It 
has 26 items to rate both the intensity and the 
frequency of the manic signs. The scale covers 
behavioural and cognitive symptoms of mania. 
This scale has been used in similar studies (Leher 
et al.,1987). Rating was done on the 1 st, 3rd, 7th, 
14th, 21st and 28th day of the admission. 
Total number of patients recruited for the 
study was 26. However, 5 patients withdrew their 
consent before four weeks. These included 3 in 
lithium group and 2 in valproate group. Patients 
who withdrew the consent had either improved 
partially or significantly (n=2) or did not want to 
continue inpatient care for personal reasons 
. (n=2); one patient developed hepatitis and hence 
was dropped from the study (drug valproate). 
The final sample consisted of 21 patients. Group 
I had 11 patients whereas group. II had 10. 
Patients in group I received lithium carbonate 
(available as 300 mg tablet each) in the range 
of 900-1500 mg. Serum lithium level was 
measured on the fifth day after starting the drug. 
Based on the serum lithium levels, the dosage 
was adjusted by the treating clinician not involved 
in the study. At the end of four weeks serum 
lithium levels ranged from 0.6 to 1.1 mEq/L in 
the group (mean=0.84 mEq/L±0.18 mEq/L). 
Patients in group II received sodium valproate 
(available as 200 mg tablet each). The loading 
dose of valproate was 20 mg/Kg. It was increased 
upto 1400 mg if needed by the clinician 
i depending on the clinical improvement. Dosage 
in the group ranged from 600 to 1400 mg. 
Monitoring of the serum levels of valproate 
though planned was not feasible due to the high 
costs involved. The total dosage of either lithium 
or valproate was given in three divided doses 
every day. The rater (HMP) was blind to the 
treatment received by patients. Any side effects 
reported was recorded but no structured 
instrument was used to assess the side effects. 
Patients with severe excitement received 
benzodiazepines for the first few days. 
Antipsychotics were not used during the study 
period at any time. 
This study was not supported by any 
pharmaceutical company. 
RESULTS 
Paired 't-test' was used to compare 
continuous variables and chi square' was used to 
compare discrete variables between the two groups. 
The dropouts were not included in the analyses. 
The two groups of men did not differ in 
terms of age, weight, and the duration of the 
current episode of mania [(p=0.159, 0.495,0.718 
respectively) (table)]. 
TABLE 
CLINCAL CHARACTERISTICS OF STUDY PATIENTS 
Variable 
Age in years 
Weight in kg 
Duration of current episode 
(in weeks) 
Dose mg/day 
BMRS score on 1 st day 
BMRS score on 28th day 
Total ben7odizepam received in mg 
Lithium 
(n=11)* 
23.73 
48.45 
5.60 
1145.45 
30773 
97.64 
39.09 
Valproate 
(n=10)* 
25.70 
52.40 
6.10 
1240.00 
290.10 
63.00 
28.89 
'mean values 
An improvement of more than 50% on 
BMRS was considered as good response The 
total score on the BMRS on first day was 
compared with the scores on 3rd, 7th, 14th, 21st 
and 28th day and a reduction of more than 50% 
in the total scores by the 28th day was considered 
as a good response. 8 of 11 in the lithium group 
(72.72%) and 8 of 10 (80%) in the valproate group 
had good resDonse. This was not statistically 
different (p=0.695). Most of the reduction in the 
total mean scores occurred in the second and 
third week in both the groups. There was no 
statistical difference between the two groups on 
the BMRS totai mean scores on the 1st day 
(p=0.431), 3rd day (p=0.837), 7th day (p=0.459). 
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14th day (p=0.297), 21st day (p=0.803) and on 
the 28th day (p=0.315) There was also no 
significant difference in the change in the scores 
between the two groups on the individual items 
of the rating scale. However, there was trend for 
better reduction of total mean scores on 28th day 
in the valproate group (fig.). There was no 
difference in dosage of benzodiazepines received 
by either group (p=0 476). 
Comparison of Mania Rating Scores 
LMumvsVilfiroale 
Fig BMRS scores of the lithium & valproate groups on the 
1",3",r, 14'", 21" & 28'" days. 
DISCUSSION 
In this controlled blind study, sodium 
valproate was found to be as effective an antimanic 
drug as lithium carbonate in acute mania. Out of 
10 patients 80% responded to 600 to 1200 mg of 
sodium valproate within two to three weeks 
indicated by a 50% reduction in total scores in 
BMRS Sodium valproate was comparable to 
lithium in the proportion of the sample that 
responded and the time frame over which they 
responded Other randomised controlled studies 
of valproate and lithium though methodologically 
different have also concluded that valproate is 
comparable to lithium in its efficacy as an antimanic 
agent in acute mania (Bowden et al.,1994; 
Freeman et al ,1992; McElroy et al.,1991). 
The percentage of good response to 
valproate was higher in this study in comparison 
to other studies - 80% vs 48% reported by 
Bowden et al (1994) and 53% reported by 
McElroy et al.(1991) and 64% by Freeman et al. 
(1992). Preselection of the sample of acute 
mania with no mixed features or comorbidity is 
probably one of the reasons for this better 
outcome in the current study. However, it is to 
be remembered that Bowden et al.(1994) 
revealed through a post-hoc analysis of their data 
that the response to valproate was unaffected 
by the presence of depressive symptoms. 
None of the recruited patients in this study 
were earlier established as poor responders to 
treatment either with lithium or antipsychotics. 
Inclusion of a sample (not by design) with no 
definite treatment resistance is probably the 
other reason for a beter response to sodium 
valproate in this study in comparison to the other 
above mentioned studies. 
Acceptance as far as side-effects were 
concerned was similar to lithium though hepatitis 
was encountered in one patient even in this small 
sample of ten. This study inspite of its stringent 
inclusion and exclusion criteria and methodology 
sample size is a limitation. The small sample 
size reduces the power of equivalence inspite 
of comparable outcome. Studies have pointed 
out that the better acceptability of valproate over 
lithium is due to its better side effect profile 
(Bowden, 1996). In this study both the drugs were 
well tolerated by the patients who completed the 
study, but it might be more accurate if a 
structured scale is used to record the side effects. 
Although' this study confirms the efficacy 
of sodium valproate in the treatment of acute 
mania in an Indian setup, it is essential and 
desirable to have more open studies with a better 
methodology with larger sample sizes and 
subtypes of mania to gain more experience, 
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